MeiraGTx Holdings plc
- Open
- 14.01
- Day high
- 14.15
- Day low
- 13.76
- Prev close
- 14.06
- Volume
- 824K
- Mkt cap
- $1.3B
- P/E (TTM)
- 18.5
- EPS (TTM)
- $0.76
- P/B
- 6.2
- P/S
- 3.4
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$2.0M over the last 3 months (0 open-market buys, 4 sales)
- 🏛Institutions accumulating (13F)
MeiraGTx Holdings plc (MGTX) is a Healthcare company listed on NASDAQ. The stock is up 88% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 4 sales (SEC Form 4). Drillr has 2 published research articles covering MGTX.
MeiraGTx Holdings plc (MGTX) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
MGTX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 13, 2026 | $-0.46 | $1.71 | +473.1% | — | — |
| Apr 16, 2026 | $-0.43 | $-0.57 | -32.6% | — | — |
| Mar 26, 2026 | $-0.60 | $0.19 | +131.7% | — | — |
| Nov 13, 2025 | $-0.50 | $-0.62 | -24.0% | $410000 | -89.4% |
| Aug 14, 2025 | $-0.52 | $-0.48 | +7.7% | $4M | -43.1% |
| Mar 13, 2025 | $-0.48 | $-0.50 | -4.2% | $21M | +1326.0% |
| May 9, 2024 | $-0.32 | $-0.77 | -140.6% | $697000 | -92.8% |
| Mar 14, 2024 | $-0.46 | $-0.47 | -2.2% | $2M | -67.8% |
| Nov 14, 2023 | $-0.63 | $-0.74 | -17.5% | $5M | +45.8% |
| Aug 10, 2023 | $-0.59 | $-0.53 | +10.2% | $4M | -15.1% |
| May 11, 2023 | $-0.65 | $-0.62 | +4.6% | $3M | -31.4% |
| Mar 14, 2023 | $0.49 | $-0.58 | -218.4% | $5M | -40.7% |
MGTX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 18, 2026 | Forbes Alexandriadirector, officer: PRESIDENT & CEO | Sell | 62,000 | $13.86 |
| Jul 21, 2026 | Giroux Richardofficer: CFO & COO | Sell | 56,000 | $12.51 |
| Jul 7, 2026 | Naylor Stuartofficer: CHIEF SCI OFCR, OPHTHALMOLOGY | Sell | 2,547 | $13.86 |
| Jul 7, 2026 | Naylor Stuartofficer: CHIEF SCI OFCR, OPHTHALMOLOGY | Sell | 25,112 | $14.90 |
| Jun 29, 2026 | Forbes Alexandriadirector, officer: PRESIDENT & CEO | Grant | 980,000 | — |
| Jun 29, 2026 | Giroux Richardofficer: CFO & COO | Grant | 980,000 | — |
| Jun 29, 2026 | Naylor Stuartofficer: CHIEF SCI OFCR, OPHTHALMOLOGY | Grant | 70,000 | — |
| Jun 29, 2026 | Wollin Robert Jofficer: GENERAL COUNSEL AND SECRETARY | Grant | 100,000 | — |
| Jun 29, 2026 | Zeldin Robert Kofficer: CHIEF MEDICAL OFFICER | Grant | 100,000 | — |
| Jun 15, 2026 | Yu Debradirector | Grant | 60,000 | — |
| Jun 15, 2026 | Mendoza Neildirector | Grant | 66,641 | — |
| Jun 15, 2026 | Seligman Nicoledirector | Grant | 60,000 | — |
| Jun 15, 2026 | SHENK THOMAS Edirector | Grant | 69,662 | — |
| Jun 15, 2026 | PERCEPTIVE ADVISORS LLCdirector, 10 percent owner: | Grant | 60,000 | — |
| Jun 15, 2026 | Harris Keith R.director | Grant | 106,441 | — |
Source: MGTX SEC Form 4 filings, latest Aug 18, 2026. For informational purposes only — not investment advice.
See the full MGTX insider & 13F page →MGTX research & analysis
Rare-Disease Gene Therapy Shifts From Sham-Surgery Control to Delivery Hardware and Endpoint Instruments
The FDA told uniQure a sham-surgery control is no longer required, moving the cost of rare-disease gene therapy onto delivery hardware and endpoint instruments.
BCDABIIBCLPTRare CNS Gene Therapy Moves Past Sham-Surgery Control
uniQure, ClearPoint and BioCardia disclosed the FDA no longer requires a sham-surgery control in rare CNS gene therapy, moving the gate to delivery hardware.
BCDACLPTCYRX
MeiraGTx Holdings plc company profile
Overview
MeiraGTx Holdings plc (NASDAQ:MGTX) is a clinical-stage gene therapy company founded in 2015 and based in New York. The company went public in June 2018 and focuses on developing innovative gene therapies to treat patients with serious diseases, particularly inherited blindness and other ocular conditions, as well as neurodegenerative diseases. MeiraGTx operates at the cutting edge of biotechnology, using advanced genetic engineering techniques to potentially cure diseases that currently have limited or no treatment options.
Business
MeiraGTx operates in the gene therapy sector of biotechnology, which involves introducing genetic material into a patient's cells to treat or prevent disease. Gene therapy represents a revolutionary approach to medicine that can potentially address the root cause of genetic disorders rather than just managing symptoms. The company's core focus areas include several therapeutic segments: 1. Ocular diseases represent the primary focus, targeting inherited forms of blindness such as Achromatopsia (complete color blindness with severe light sensitivity), X-Linked Retinitis Pigmentosa (a genetic condition causing progressive vision loss), and RPE65-deficiency (a rare inherited retinal dystrophy). These conditions affect the retina's ability to process light and convert it into visual signals, often leading to severe vision impairment or blindness from an early age. 2. Xerostomia treatment focuses on severe dry mouth conditions, particularly those resulting from radiation treatment for head and neck cancers, as well as Sjögren's syndrome, an autoimmune condition. Xerostomia significantly impacts patients' quality of life, affecting their ability to eat, speak, and maintain oral health. 3. Neurodegenerative diseases including Parkinson's disease and amyotrophic lateral sclerosis (ALS), represent the company's expansion into treating progressive neurological conditions that currently have limited therapeutic options. The company also maintains a research collaboration with Janssen Pharmaceuticals to develop regulatable gene therapy treatments using MeiraGTx's proprietary riboswitch technology, which allows for controlled activation of therapeutic genes.
Competitive moat
MeiraGTx's competitive moat is moderate but developing, built primarily around its specialized expertise in ocular gene therapy and proprietary riboswitch technology platform. The company benefits from several defensive characteristics typical of biotechnology firms. The company's strongest moat lies in its deep expertise in retinal gene therapy, where it has developed specialized knowledge in targeting specific cells within the eye and delivering therapeutic genes effectively. This expertise creates barriers for competitors who would need years to develop similar capabilities. The company's riboswitch technology, which allows for controlled gene expression, represents a potentially differentiating platform that could provide advantages across multiple therapeutic areas. Regulatory barriers also provide some protection, as the FDA approval process for gene therapies is complex and expensive, requiring extensive safety and efficacy data. Companies that successfully navigate this process first gain significant advantages through market exclusivity periods. However, the moat faces several challenges. The gene therapy field is rapidly evolving with numerous well-funded competitors, including larger pharmaceutical companies with greater resources. Platform risk is significant, as breakthrough technologies from competitors could potentially obsolete current approaches. Additionally, the company lacks the manufacturing scale and distribution networks of larger pharmaceutical companies, making it vulnerable to partnership dependencies. The intellectual property landscape in gene therapy is complex and competitive, with potential for patent disputes. The company's moat will ultimately depend on successfully translating its clinical programs into approved therapies and establishing market leadership in its chosen therapeutic areas before competitors can catch up.
Risks & safety
MeiraGTx presents moderate to high financial risk typical of clinical-stage biotechnology companies, with limited margin of safety due to cash burn and lack of product revenue. • Cash position: $66.5 million in cash and short-term investments as of Q1 2025, down from $103.7 million at year-end 2024, indicating rapid cash consumption • Burn rate: Free cash flow of -$38.5 million in Q1 2025 and -$109.4 million for full year 2024, suggesting approximately 1.5-2 years of runway at current burn rates • Debt levels: Relatively low debt-to-equity ratio of 0.10 as of Q1 2025, indicating minimal debt burden • Current ratio: 1.53 in Q1 2025, showing adequate short-term liquidity but declining from 2.03 in Q4 2024 Valuation considerations: • Trading at negative enterprise value multiples due to losses, making traditional valuation metrics less meaningful • Price-to-book ratio of 16.2x indicates significant premium to tangible assets • Market cap of approximately $482 million against minimal revenue base creates high execution risk Other risk factors: Heavy dependence on successful clinical trial outcomes, regulatory approval risks, and potential need for additional capital raises that could dilute existing shareholders. The company's survival depends on either achieving significant clinical milestones or securing additional partnership funding.
Recent development
Based on the financial data trends, MeiraGTx has been advancing its clinical pipeline while managing the typical challenges of a development-stage biotechnology company. The company has maintained its focus on ocular gene therapies while expanding into neurodegenerative diseases. Clinical program advancement has been the primary strategic focus, with the company progressing multiple Phase 1/2 clinical trials across its core therapeutic areas. The variable revenue pattern, particularly the spike to $21.4 million in Q4 2024, suggests significant milestone achievements or partnership activities during that period. Partnership strategy appears to be a key component of the company's development approach, as evidenced by the collaboration with Janssen Pharmaceuticals and the fluctuating revenue streams that typically indicate milestone-based partnerships. This strategy allows MeiraGTx to leverage larger pharmaceutical companies' resources while retaining rights to its core technologies. Platform development has continued around the proprietary riboswitch technology, which represents a potentially differentiating capability for creating regulatable gene therapies. This technology platform could provide competitive advantages across multiple therapeutic applications. The company has maintained its research and development intensity while managing cash resources, though the increasing burn rate from $73.1 million in 2022 to $109.4 million in 2024 reflects the natural progression of clinical trials into more expensive later-stage studies. The expansion into additional therapeutic areas, including Sjögren's syndrome-related xerostomia, demonstrates the company's efforts to broaden its addressable market opportunities.
MGTX company profile · for informational purposes only — not investment advice.
Track MGTX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free